Cargando…
Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine trial.
Autores principales: | Lin, Dan-Yu, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Neuzil, Kathleen M., Corey, Lawrence, Miller, Jacqueline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178430/ https://www.ncbi.nlm.nih.gov/pubmed/35675078 http://dx.doi.org/10.1001/jamanetworkopen.2022.15984 |
Ejemplares similares
-
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021) -
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020) -
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022) -
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021) -
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)